(Q47815963)

5 February 2018

title

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. (English)

1 reference

5 February 2018

main subject

phase III clinical trial

0 references

bevacizumab

1 reference

triple-negative breast cancer

inferred from title

1 reference

20

1 reference

5 February 2018

Julia Brown

2

object named as

Julia Brown

1 reference

5 February 2018

16

Tadeusz Pienkowski

1 reference

5 February 2018

Seock-Ah Im

19

object named as

Seock-Ah Im

1 reference

5 February 2018

Masakazu Toi

9

object named as

Masakazu Toi

1 reference

5 February 2018

author name string

David Cameron

1

1 reference

5 February 2018

Rebecca Dent

3

1 reference

5 February 2018

Christian Jackisch

4

1 reference

5 February 2018

John Mackey

5

1 reference

5 February 2018

Xavier Pivot

6

1 reference

5 February 2018

Guenther G Steger

7

1 reference

5 February 2018

Thomas M Suter

8

1 reference

5 February 2018

Mahesh Parmar

10

1 reference

5 February 2018

Rita Laeufle

11

1 reference

5 February 2018

Young-Hyuck Im

12

1 reference

5 February 2018

Gilles Romieu

13

1 reference

5 February 2018

Vernon Harvey

14

1 reference

5 February 2018

Oleg Lipatov

15

1 reference

5 February 2018

Paul Cottu

17

1 reference

5 February 2018

Arlene Chan

18

1 reference

5 February 2018

Lida Bubuteishvili-Pacaud

21

1 reference

5 February 2018

Volkmar Henschel

22

1 reference

5 February 2018

Regula J Deurloo

23

1 reference

5 February 2018

Celine Pallaud

24

1 reference

5 February 2018

Richard Bell

25

1 reference

5 February 2018

publication date

7 August 2013

1 reference

5 February 2018

Lancet Oncology Commission

published in

1 reference

5 February 2018

volume

14

1 reference

5 February 2018

page(s)

933-942

1 reference

5 February 2018

issue

10

1 reference

5 February 2018

Triple-negative breast cancer: clinical features and patterns of recurrence

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

New automated multiplex assay for bone turnover markers in osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Adjuvant bevacizumab in colon cancer: where did we go wrong?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Why do targeted agents not work in the adjuvant setting in colon cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970335-8

7 January 2021

10.1016/S1470-2045(13)70335-8

Identifiers

DOI

1 reference

5 February 2018

release_4dbcgsuzhng3vduzd6jivdrhxm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4dbcgsuzhng3vduzd6jivdrhxm

24 November 2022

mapped directly with Wikidata item

PubMed ID

23932548

1 reference

5 February 2018